How does the 73,402-share stock option for Electra Therapeutics (ETRA) vest?

The 73,402-share stock option with a $15.00 exercise price vests in 1/48th monthly installments, with vesting commencing on September 17, 2026, and the option expires on September 16, 2036.

Does the Form 3 for Electra Therapeutics (ETRA) report any insider share purchases or sales?

No purchases or sales are reported. The Form 3 lists existing stock option positions for Principal Accounting Officer David J. Tucker, describing the number of underlying shares, exercise prices, expiration dates, and vesting schedules, without reporting any transactions changing those holdings.

Electra Therapeutics PAO reports two 2036 stock options

Q: What are the terms of David J. Tucker’s 114,000-share stock option at Electra Therapeutics (ETRA)?

The 114,000-share option has an exercise price of $4.96 per share, expires on April 8, 2036, and vests with one-quarter of the shares vesting one year after March 30, 2026 and the remaining three-quarters vesting in equal monthly installments thereafter.

Q: Are any of David J. Tucker’s stock options at Electra Therapeutics (ETRA) early exercisable?

Yes. The 114,000-share option at an exercise price of $4.96 per share is described as early exercisable, subject to Electra Therapeutics’ contractual right of repurchase on the shares obtained through such early exercise.

Electra Therapeutics’ principal accounting officer disclosed two long-dated stock option awards with time-based monthly vesting schedules.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Electra Therapeutics, Inc. (ETRA) reported initial insider holdings for Principal Accounting Officer David J. Tucker. He holds two employee stock options for common stock: one covering 114,000 shares at an exercise price of $4.96 per share expiring on April 8, 2036, and another covering 73,402 shares at an exercise price of $15.00 per share expiring on September 16, 2036. The first option vests with one-quarter of the shares vesting one year after March 30, 2026 and the remainder in equal monthly installments over the following three years and is early exercisable subject to the company’s repurchase right. The second option vests in equal monthly installments beginning on September 17, 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Tucker David J.

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy) ^F1	--	--	--
holding	Employee Stock Option (right to buy) ^F2	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 187,402 contracts (Direct)

Footnotes (2)

F1. 1/4th of the total shares subject to this option vested one year after March 30, 2026, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.

Key Figures

Option underlying shares: 114,000 shares Exercise price: $4.96 per share Expiration date: April 8, 2036 +5 more

8 metrics

Option underlying shares 114,000 shares First employee stock option on common stock held by David J. Tucker

Exercise price $4.96 per share Exercise price for the 114,000-share stock option expiring April 8, 2036

Expiration date April 8, 2036 Expiration of the 114,000-share stock option

Second option underlying shares 73,402 shares Second employee stock option on common stock held by David J. Tucker

Exercise price $15.00 per share Exercise price for the 73,402-share stock option expiring September 16, 2036

Expiration date September 16, 2036 Expiration of the 73,402-share stock option

Vesting start date (first option) One-year cliff after March 30, 2026 First option: one-quarter vests after one year, remainder monthly

Vesting start date (second option) September 17, 2026 Second option begins vesting in equal monthly installments from this date

Key Terms

early exercisable, right of repurchase, vest monthly

3 terms

early exercisable financial

"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase."

right of repurchase financial

"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase."

vest monthly financial

"1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider holdings did Electra Therapeutics (ETRA) disclose for David J. Tucker?

The company disclosed that Principal Accounting Officer David J. Tucker holds two employee stock options on common stock, covering 114,000 shares at $4.96 per share and 73,402 shares at $15.00 per share, both expiring in 2036, with time-based vesting.

Are any of David J. Tucker’s stock options at Electra Therapeutics (ETRA) early exercisable?

Yes. The 114,000-share option at an exercise price of $4.96 per share is described as early exercisable, subject to Electra Therapeutics’ contractual right of repurchase on the shares obtained through such early exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/18/2026 - 08:25 PM EDT Accepted by SEC EDGAR 09/18/2026 - 04:28 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tucker David J.

(Last)

(First)

(Middle)

C/O ELECTRA THERAPEUTICS, INC.

230 E GRAND AVENUE, SUITE S-100

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2026

3. Issuer Name and Ticker or Trading Symbol
Electra Therapeutics, Inc. [ ETRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Principal Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽¹⁾	04/08/2036	Common Stock	114,000	$4.96	D
Employee Stock Option (right to buy)	⁽²⁾	09/16/2036	Common Stock	73,402	$15	D

Explanation of Responses:

1. 1/4th of the total shares subject to this option vested one year after March 30, 2026, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

2. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.

	/s/ Jamie Kitano, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR